Barclays PLC Alvotech Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Alvotech stock. As of the latest transaction made, Barclays PLC holds 15,860 shares of ALVO stock, worth $202,690. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,860

Holding current value

$202,690

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 13, 2025	BUY	$11.28 - $13.2 $178,900 - $209,352	15,860 New	15,860 $210,000
Q2 2022 Aug 12, 2022	BUY	$8.21 - $11.19 $10,311 - $14,054	1,256 New	1,256 $10,000

Others Institutions Holding ALVO

# of Institutions

Shares Held

14.8M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

3.2M
Shares

$40.9 Million
0.0% of portfolio
Bracebridge Capital, LLC

2.71M
Shares

$34.6 Million
5.53% of portfolio
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca

1.93M
Shares

$24.6 Million
0.65% of portfolio
Morgan Stanley New York, NY

1.48M
Shares

$18.9 Million
0.0% of portfolio
Littlejohn & CO LLC

1.32M
Shares

$16.9 Million
7.91% of portfolio

View Full List

About Alvotech

Ticker ALVO
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 248,650,000
Market Cap $3.18B
Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...

More about ALVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account